KRAS G12D Vaccines (ELI-002)

Type: vaccine

Status: Investigational (MSKCC trial)

Developer: Elicio Therapeutics

Breakthrough Summary

No summary available.

Mechanism of Action

Neoantigen vaccine targeting KRAS G12D mutation found in 90%+ of pancreatic cancers

Year: 2024-2026